First Long-Term Study Evaluating The Use Of Plasma Energy To Treat Endometrioma
Three-year data on the PlasmaJet® surgical system presented in Paris at the 21st Annual European Society for Gynaecological Endoscopy (ESGE) Congress
At the 21st Annual European Society for Gynaecological Endoscopy (ESGE) Congress held in Paris, the results were presented from a three-year, cohort study, titled Postoperative Recurrences and Fertility Following Endometrioma Ablation Using Plasma Energy: Retrospective Assessment of a 3-Year Experience, that retrospectively assessed postoperative ovarian endometriomas recurrence and fertility.
The study, led by principal investigator Professor Horace Roman, M.D. PhD. Rouen University Hospital, Rouen, France included 55 patients who had unilateral or bilateral ovarian endometriomas removed by PlasmaJet ® ablation. After a mean follow-up of 20 months (range 12-39 months), 67 percent of women who wished to become pregnant had conceived, 59 percent of them spontaneously. These are particularly promising results given that 75% of the study cohort suffered from deep infiltrating endometriosis, a condition often plagued with a poor fertility diagnosis.
The study findings were presented by Prof. Roman at the 21st Annual ESGE Congress in Paris, France on September 12, 2012. At a dedicated symposium on the subject, Prof. Roman detailed the benefits that PlasmaJet could have in surgery for patients with ovarian endometriomas, specifically those looking to conceive or wishing to preserve the option. As Prof. Roman noted, current surgical methods, such as cystectomy, often lead to the unintentional removal of ovarian tissue surrounding the cyst, depleting an already limited ovarian reserve, thus placing the patient's fertility at further risk. According to national surveys performed by the Centers for Disease Control, each year, hundreds of thousands of women are diagnosed with painful endometriosis-related conditions in the U.S. alone, and more than 50,000 are treated surgically for endometriosis of the ovary, also referred to as an endometrioma. 
"The results of this study represent a significant step forward for women whose fertility has been threatened by ovarian endometriomas and by the deleterious consequences of endometrioma cystectomies," said Prof. Roman. "The opportunity that plasma energy provides surgeons to cut or ablate, yet significantly spare, vital ovarian tissue in patients with ovarian endometriomas may lead to it being a first line surgical technique in women intending to conceive."
"We've spent the last several years working closely with the clinical community, evaluating the use of electrosurgical and other tools, and together determined there was a better way to treat the tissue in and around the ovaries," said Rick Morello, chief executive officer, Plasma Surgical. "The tissue sparing outcome resulting from PlasmaJet is ideal for this region of the human body."
PlasmaJet is currently available for sale in the United States, United Kingdom, France, The Netherlands, Belgium, Switzerland, Russia and Canada.
Source: The Annual European Society for Gynaecological Endoscopy (ESGE)
Please use one of the following formats to cite this article in your essay, paper or report:
The Annual European Society for Gynaecological End. "First Long-Term Study Evaluating The Use Of Plasma Energy To Treat Endometrioma." Medical News Today. MediLexicon, Intl., 15 Sep. 2012. Web.
26 Aug. 2016. <http://www.medicalnewstoday.com/releases/250261.php>
The Annual European Society for Gynaecological End. (2012, September 15). "First Long-Term Study Evaluating The Use Of Plasma Energy To Treat Endometrioma." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.